{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:53:01Z","timestamp":1794923581887,"version":"4.9.1"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate practice patterns and long-term complications of proliferative diabetic retinopathy treatment outside Diabetic Retinopathy Clinical Research Network's Protocol S.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort study using Vestrum Health Retina Database included 26,632 treatment-naive eyes receiving antivascular endothelial growth factor injections for proliferative diabetic retinopathy between 2016 and 2021. Primary outcomes were concordance with Protocol S, defined as four antivascular endothelial growth factor injections within 14 weeks of baseline, and 6-month gaps in care, assessed via multivariable logistic regressions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among eyes with diabetic macular edema, those concordant with Protocol S had mean visual acuity gain of +3.0 letters compared with \u22120.6 letters among those not concordant with Protocol S at 2 years. Over 40% of patients became loss to follow-up within 1 year. Those experiencing 6-month gaps in care within the first year had higher rates of vitrectomy, retinal detachment, and neovascular glaucoma at 2 years. Patients with diabetic macular edema were more likely to be concordant, whereas those with Early Treatment Diabetic Retinopathy Study letter score &gt;70 were less likely to be concordant with Protocol S regimen relative to those without diabetic macular edema and Early Treatment Diabetic Retinopathy Study letter score between 24 and 40, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The frequent follow-up appointments and repeat treatments necessary for antivascular endothelial growth factor monotherapy in proliferative diabetic retinopathy can pose challenges to maintaining the required schedule and can result in worse visual acuity outcomes and increased ocular complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004440","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T18:00:10Z","timestamp":1741716010000},"page":"1303-1312","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["VISUAL OUTCOMES AND ADHERENCE CHALLENGES IN PROLIFERATIVE DIABETIC RETINOPATHY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY IN THE CLINICAL PRACTICE SETTING"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-2962","authenticated-orcid":false,"given":"Jay R.","family":"Maturi","sequence":"first","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Boucher","sequence":"additional","affiliation":[{"name":"Vestrum Health, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusirini","family":"Fernando","sequence":"additional","affiliation":[{"name":"Vestrum Health, Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne W.","family":"Scott","sequence":"additional","affiliation":[{"name":"Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250702","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.2147\/OPTH.S374165","article-title":"A paradigm shift in the management approaches of proliferative diabetic retinopathy: role of anti-VEGF therapy","volume":"16","author":"Raman","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"R3-20250702","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00417-009-1147-x","article-title":"Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy","volume":"247","author":"Shimura","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R4-20250702","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1755-3768.1994.tb07181.x","article-title":"The effect of panretinal laser photocoagulation on visual acuity, visual fields and on subjective visual impairment in preproliferative and early proliferative diabetic retinopathy","volume":"72","author":"Henricsson","year":"1994","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R5-20250702","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"R6-20250702","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/24741264231221607","article-title":"Effect of race and insurance status on treatment and outcomes in diabetic retinopathy: analysis of 43 274 eyes using the IRIS registry","volume":"8","author":"Maturi","year":"2024","journal-title":"J Vitreoretin Dis"},{"key":"R7-20250702","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s10900-013-9681-1","article-title":"Traveling towards disease: transportation barriers to health care access","volume":"38","author":"Syed","year":"2013","journal-title":"J Community Health"},{"key":"R8-20250702","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"key":"R9-20250702","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","article-title":"Loss to follow-up in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy in the United States in the IRIS\u00ae Registry","volume":"130","author":"Khurana","year":"2023","journal-title":"Ophthalmology"},{"key":"R10-20250702","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R11-20250702","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaophthalmol.2021.4103","article-title":"Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy","volume":"139","author":"Maguire","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R12-20250702","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.oret.2024.04.016","article-title":"Loss to follow up in patients with proliferative diabetic retinopathy treated with anti-VEGF therapy and\/or panretinal photocoagulation in the United States","volume":"8","author":"Khurana","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R13-20250702","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.oret.2018.11.002","article-title":"Loss to follow-up after intravitreal anti-vascular endothelial growth factor injections in patients with diabetic macular edema","volume":"3","author":"Gao","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R14-20250702","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajo.2020.03.011","article-title":"Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice","volume":"215","author":"Suresh","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"R15-20250702","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0002-9394(76)90292-0","article-title":"Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group","volume":"81","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"R16-20250702","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11892-021-01403-6","article-title":"Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema","volume":"21","author":"Everett","year":"2021","journal-title":"Curr Diab Rep"},{"key":"R17-20250702","first-page":"583","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group","volume":"88","year":"1981","journal-title":"Ophthalmology"},{"key":"R18-20250702","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/08820538.2016.1228397","article-title":"Evidence-based treatment of diabetic retinopathy","volume":"32","author":"El Rami","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"R19-20250702","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jamaophthalmol.2024.1844","article-title":"Progression to pars plana vitrectomy in patients with proliferative diabetic retinopathy","volume":"142","author":"Alsoudi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R20-20250702","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"R21-20250702","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/09286586.2022.2127787","article-title":"Loss to follow up among glaucoma patients at a tertiary eye center over 10 years: incidence, risk factors, and clinical outcomes","volume":"30","author":"Williams","year":"2023","journal-title":"Ophthalmic Epidemiol"},{"key":"R22-20250702","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaophthalmol.2017.0821","article-title":"Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab","volume":"135","author":"Bressler","year":"2017","journal-title":"JAMA Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:08:06Z","timestamp":1785856086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004440","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}